Serious asthma events with Budesonide Plus Formoterol vs. Budesonide Alone

New England Journal of Medicine

Volumn 375, Issue 9, 2016, Pages 850-860

  Peters, Stephen P ^a   Bleecker, Eugene R ^a   Canonica, Giorgio W ^b   Park, Yong B ^c   Ramirez, Ricardo ^d   Hollis, Sally ^e   Fjallbrant, Harald ^f   Jorup, Carin ^f   Martin, Ubaldo J ^e  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c Hallym University   (South Korea)

^d Centro de Investigacion y Atencion Integral   (Mexico)

^e ASTRAZENECA   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE; GLUCOCORTICOID; LONG ACTING DRUG; SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DELAYED RELEASE FORMULATION; FORMOTEROL FUMARATE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; ASTHMA; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTRACHEAL INTUBATION; FEMALE; HOSPITALIZATION; HUMAN; INHALER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MONOTHERAPY; MULTICENTER STUDY; OPEN LABEL INHALER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DELAYED RELEASE FORMULATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORMOTEROL FUMARATE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84986000867     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1511190     Document Type: Article

References (24)

1. Global Initiative for Asthma (GINA). 2016 GINA report: Global strategy for asthma management and prevention. 2016 (http://ginasthma .org/ 2016-gina-report -global-strategy-for-asthma-management -and-prevention/ ).
2. Lofdahl CG, Chung KF. Long-acting beta 2-adrenoceptor agonists: A new perspective in the treatment of asthma. Eur Respir J 1991; 4: 218-26.
3. Nelson HS, Carr W, Nathan R, Portnoy JM. Update on the safety of long-acting beta-agonists in combination with inhaled corticosteroids for the treatment of asthma. Ann Allergy Asthma Immunol 2009; 102: 11-5.
4. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034-7.
5. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26.
6. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: A review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33: 21-32.
7. Sears MR, Radner F. Safety of formoterol in asthma clinical trials: An update. Eur Respir J 2014; 43: 103-14.
8. Nelson H, Bonuccelli C, Radner F, et al. Safety of formoterol in patients with asthma: Combined analysis of data from double-blind, randomized controlled trials. J Allergy Clin Immunol 2010; 125(2): 390- 396.e8.
9. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; 362: 1169-71.
10. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med 2011; 364: 2473-5.
11. National Institutes of Health, National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program Coordinating Committee. Expert Panel report 3: Guidelines for the diagnosis and management of asthma (EPR-3). 2007 (http://www .nhlbi .nih .gov/ health-pro/ guidelines/ current/ asthma-guidelines/ full-report).
12. Global Initiative for Asthma (GINA). 2010 GINA report: Global strategy for asthma management and prevention. 2010 (http://ginasthma .org).
13. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-38.
14. National Asthma Council Australia. Inhaled corticosteroids: A practical perspective. 2003 (https:/ / www .nationalasthma .org .au/ ).
15. Sears MR, Radner F. Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 2009; 103: 1960-8.
16. Stempel DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med 2016; 374: 1822-30.
17. Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. highdose salmeterol/fluticasone. Respir Med 2007; 101: 2437-46.
18. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61: 725-36.
19. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-36.
20. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: A randomised controlled, doubleblind study. Lancet 2006; 368: 744-53.
21. Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: A randomized, double-blind trial. Chest 2006; 129: 246-56.
22. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/ formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403-18.
23. Brown RW, O'Brien CD, Martin UJ, Uryniak T, Lampl KL. Long-term safety and asthma control measures with a budesonide/ formoterol pressurized metered-dose inhaler in African American asthmatic patients: A randomized controlled trial. J Allergy Clin Immunol 2012; 130(2): 362-7. e9
24. Ortega VE, Hawkins GA, Moore WC, et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: A genetic study. Lancet Respir Med 2014; 2: 204-13.